Establishment Labs Holdings (ESTA) Stock Overview
A medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ESTA from our risk checks.
ESTA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Establishment Labs Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$85.81 |
| 52 Week High | US$90.50 |
| 52 Week Low | US$33.35 |
| Beta | 1.11 |
| 1 Month Change | 21.39% |
| 3 Month Change | 46.18% |
| 1 Year Change | 97.72% |
| 3 Year Change | 27.96% |
| 5 Year Change | 3.37% |
| Change since IPO | 246.71% |
Recent News & Updates
Narrative Update • Jun 18
ESTA: Fair 2026 Outlook Will Balance Overdone Selloff And Execution Risks
Analysts have nudged their price target on Establishment Labs Holdings higher to about $90.67 from $89, citing what they view as an overdone selloff and updated views on fair value and future earnings multiples. Analyst Commentary Recent Street research on Establishment Labs Holdings highlights a mix of optimism and caution as analysts reassess what they view as an overdone selloff and revisit their valuation work.
Narrative Update • Jun 03
ESTA: Rebased Expectations And Raised 2026 Guidance Will Support Measured Repricing
Analysts have lifted their price target on Establishment Labs Holdings by $11 to $74, pointing to what they see as an overdone selloff and reaffirming that sector fundamentals in medical technology remain healthy despite recent volatility. Analyst Commentary Recent research updates on Establishment Labs Holdings highlight a mixed backdrop, with some analysts pointing to what they view as an overdone selloff while others trim expectations and flag risks around execution and valuation.Narrative Update • May 17
ESTA: Raised 2026 Guidance And Profitability Will Support Bullish Repricing
Analysts have lifted their consolidated price target on Establishment Labs to $76.00, supported by recent research that cites updated Q4-driven models, sustained profitability, and reinforced confidence in upcoming US guidance. Analyst Commentary Street research around Establishment Labs Holdings has been active, with multiple firms updating their models following the latest Q4 results and guidance.Recent updates
Narrative Update • Jun 18
ESTA: Fair 2026 Outlook Will Balance Overdone Selloff And Execution Risks
Analysts have nudged their price target on Establishment Labs Holdings higher to about $90.67 from $89, citing what they view as an overdone selloff and updated views on fair value and future earnings multiples. Analyst Commentary Recent Street research on Establishment Labs Holdings highlights a mix of optimism and caution as analysts reassess what they view as an overdone selloff and revisit their valuation work.Narrative Update • Jun 03
ESTA: Rebased Expectations And Raised 2026 Guidance Will Support Measured Repricing
Analysts have lifted their price target on Establishment Labs Holdings by $11 to $74, pointing to what they see as an overdone selloff and reaffirming that sector fundamentals in medical technology remain healthy despite recent volatility. Analyst Commentary Recent research updates on Establishment Labs Holdings highlight a mixed backdrop, with some analysts pointing to what they view as an overdone selloff while others trim expectations and flag risks around execution and valuation.Narrative Update • May 17
ESTA: Raised 2026 Guidance And Profitability Will Support Bullish Repricing
Analysts have lifted their consolidated price target on Establishment Labs to $76.00, supported by recent research that cites updated Q4-driven models, sustained profitability, and reinforced confidence in upcoming US guidance. Analyst Commentary Street research around Establishment Labs Holdings has been active, with multiple firms updating their models following the latest Q4 results and guidance.Narrative Update • Apr 29
ESTA: Mixed Research Views And 2026 Outlook Will Shape Earnings Profile
Narrative Update on Establishment Labs Holdings The updated analyst price target for Establishment Labs Holdings has shifted from about $75 to roughly $69, as analysts factor in slightly softer modeled revenue growth and profit margins, partly offset by a higher assumed future P/E and mixed recent price target moves across the Street. Analyst Commentary Recent Street research on Establishment Labs Holdings presents a mixed picture, with some more optimistic voices balancing out a set of cautious adjustments.
Narrative Update • Apr 14
ESTA: Sustained Adj EBITDA Profitability And US Guidance Will Support Repricing
Analysts have revised the price target for Establishment Labs Holdings to $100, reflecting updated views on discount rates, margins, and long term P/E assumptions following recent sector wide model adjustments and company specific Q4 and guidance commentary. Analyst Commentary Recent research coverage on Establishment Labs Holdings has centered on how the company’s Q4 results, guidance, and sector wide model resets feed into valuation frameworks, particularly around updated P/E assumptions and revised discount rates.Narrative Update • Mar 31
ESTA: Sustained EBITDA Profitability And 2026 Guidance Will Support Stronger Outlook
Narrative Update on Establishment Labs Holdings The updated analyst price target of $89.00 for Establishment Labs Holdings, which held steady compared with the prior $89 level, reflects analysts balancing recent target increases tied to Q4 results and 2026 guidance with a sector wide recalibration in medical technology and a view among some that the recent selloff was unwarranted and overdone. Analyst Commentary Recent Street research on Establishment Labs Holdings highlights a mix of supportive and cautious views as analysts update their models following Q4 results, 2026 guidance and volatility across the medical technology group.Narrative Update • Mar 17
ESTA: Sustained EBITDA Profitability And U S Guidance Will Support Stronger Outlook
Analysts have nudged the fair value estimate for Establishment Labs Holdings to $89.00, reflecting updated price targets across the Street that incorporate recent Q4 results, refreshed guidance, and sector wide medtech adjustments. Analyst Commentary Street research around Establishment Labs Holdings has shifted meaningfully following Q4 results and updated guidance, with a spread of targets from $74 to $100 helping anchor the new $89.00 fair value estimate.Narrative Update • Mar 03
ESTA: Sustained Adj EBITDA Profitability And US Guidance Will Drive Repricing
Analysts have raised their average fair value estimate for Establishment Labs Holdings to $100 from $90, citing recent price target increases and updated models that reflect Q4 results, sustained Adj. EBITDA profitability, and a more constructive view on 2026 and US guidance.Narrative Update • Feb 17
ESTA: 2025 Revenue Guidance And Margin Outlook Will Support Repricing
Analysts have maintained their $90.00 price target for Establishment Labs Holdings, citing updated assumptions that reflect a lower discount rate, modestly higher revenue growth and profit margin expectations, as well as a slightly reduced future P/E multiple. What's in the News The company issued preliminary revenue guidance for the fourth quarter of 2025, with unaudited revenue expected between $64.0 million and $65.0 million, including $17.0 million to $17.5 million from Motiva sales in the United States (Key Developments).Narrative Update • Feb 03
ESTA: Positive EBITDA And U S Expansion Will Support Stronger Forward Outlook
Narrative Update on Establishment Labs Holdings The analyst price target for Establishment Labs Holdings has been lifted from about US$79.67 to roughly US$83.25, as analysts point to recent Q3 revenue and EBITDA beats, an outlook for 2025 revenue above the prior guidance midpoint, and expectations for stronger Motiva sales as key drivers of their updated assumptions. Analyst Commentary Recent research notes give you a clearer picture of how the Street is thinking about Establishment Labs Holdings after its latest Q3 update and guidance commentary.Narrative Update • Jan 20
ESTA: First Positive EBITDA And 2025 Outlook Will Support Repricing
Analysts have raised their price target on Establishment Labs Holdings to an implied fair value of $90, up from $70, citing better than expected Q3 results, the first quarter of positive EBITDA, and increased confidence in management's updated revenue expectations for 2025. Analyst Commentary Bullish analysts are framing the recent Q3 report as a key proof point for Establishment Labs Holdings, highlighting that revenue and adjusted EBITDA figures were ahead of prior consensus expectations.Narrative Update • Jan 06
ESTA: Q3 Profitability And U.S. Expansion Will Reshape Earnings Profile
Narrative Update The analyst fair value estimate for Establishment Labs Holdings has shifted from US$40.00 to US$75.00. Analysts attributed this change to stronger than expected Q3 revenue, the company’s first quarter of positive EBITDA, increased 2025 revenue expectations, and greater conviction in the U.S. Motiva sales potential as key drivers of their higher price targets.Analysis Article • Jan 02
Revenues Not Telling The Story For Establishment Labs Holdings Inc. (NASDAQ:ESTA)
Establishment Labs Holdings Inc.'s ( NASDAQ:ESTA ) price-to-sales (or "P/S") ratio of 11.1x may look like a poor...Narrative Update • Dec 20
ESTA: Positive EBITDA And U S Expansion Will Support Measured Forward Outlook
Analysts have modestly increased their price target for Establishment Labs Holdings to approximately $80 per share from about $74, citing stronger than expected Q3 results, the company's first quarter of positive EBITDA, as well as growing confidence in sustained revenue growth and U.S. Motiva sales expansion. Analyst Commentary Street research following the Q3 print reflects a predominantly constructive stance on Establishment Labs, with analysts highlighting both upside drivers and lingering risks that could influence valuation and execution.Narrative Update • Dec 05
ESTA: Positive EBITDA And U S Expansion Will Support Balanced Outlook
Analysts have lifted their price target on Establishment Labs Holdings, increasing fair value estimates to about $74 from roughly $71, supported by stronger than expected Q3 results, the company’s first positive EBITDA, and raised 2025 revenue expectations. Analyst Commentary Recent research notes highlight a generally constructive stance on Establishment Labs Holdings, with multiple firms lifting price targets following the latest Q3 results and updated 2025 guidance.Narrative Update • Nov 21
ESTA: Continued U S Sales Gains And Improved Margins Will Support Balanced Outlook
Analysts have raised their price target for Establishment Labs Holdings from $62.22 to $71.33 per share, reflecting continued outperformance in Q3 results, improving profit margins, and increased confidence in future revenue growth. Analyst Commentary Analysts have responded to Establishment Labs Holdings' recent performance with revised outlooks, highlighting both areas of strength and potential challenges for the company.Analysis Article • Nov 08
US$62.22 - That's What Analysts Think Establishment Labs Holdings Inc. (NASDAQ:ESTA) Is Worth After These Results
A week ago, Establishment Labs Holdings Inc. ( NASDAQ:ESTA ) came out with a strong set of third-quarter numbers that...Narrative Update • Nov 07
ESTA: Positive Earnings And U S Market Expansion Will Drive Balanced Outlook
The analyst price target for Establishment Labs Holdings has increased from $55.44 to $62.22 per share. Analysts cite strong Q3 results, improved profit margins, and raised revenue guidance as key drivers of this upward revision.Analysis Article • Jul 22
We Think Establishment Labs Holdings (NASDAQ:ESTA) Has A Fair Chunk Of Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Narrative • May 28
Minimally Invasive Procedures Will Expand US And Global Aesthetic Markets
Increasing demand for minimally invasive cosmetic breast procedures and strong U.S. market performance are driving revenue growth and higher margins.Analysis Article • Apr 22
The Price Is Right For Establishment Labs Holdings Inc. (NASDAQ:ESTA) Even After Diving 26%
Establishment Labs Holdings Inc. ( NASDAQ:ESTA ) shares have had a horrible month, losing 26% after a relatively good...Analysis Article • Apr 09
Here's Why Establishment Labs Holdings (NASDAQ:ESTA) Can Afford Some Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Mar 19
What Is Establishment Labs Holdings Inc.'s (NASDAQ:ESTA) Share Price Doing?
Establishment Labs Holdings Inc. ( NASDAQ:ESTA ), might not be a large cap stock, but it received a lot of attention...Analysis Article • Mar 01
Establishment Labs Holdings Inc. (NASDAQ:ESTA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
The investors in Establishment Labs Holdings Inc. 's ( NASDAQ:ESTA ) will be rubbing their hands together with glee...Analysis Article • Feb 28
After Leaping 29% Establishment Labs Holdings Inc. (NASDAQ:ESTA) Shares Are Not Flying Under The Radar
Establishment Labs Holdings Inc. ( NASDAQ:ESTA ) shareholders are no doubt pleased to see that the share price has...Analysis Article • Jan 14
Establishment Labs Holdings Inc. (NASDAQ:ESTA) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
Establishment Labs Holdings Inc. ( NASDAQ:ESTA ) shares have had a horrible month, losing 27% after a relatively good...Analysis Article • Nov 25
Is Establishment Labs Holdings Inc. (NASDAQ:ESTA) Trading At A 21% Discount?
Key Insights The projected fair value for Establishment Labs Holdings is US$54.78 based on 2 Stage Free Cash Flow to...Analysis Article • Sep 23
Is Establishment Labs Holdings (NASDAQ:ESTA) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Aug 11
Earnings Release: Here's Why Analysts Cut Their Establishment Labs Holdings Inc. (NASDAQ:ESTA) Price Target To US$59.86
It's been a pretty great week for Establishment Labs Holdings Inc. ( NASDAQ:ESTA ) shareholders, with its shares...Analysis Article • Jul 23
Shareholders Should Be Pleased With Establishment Labs Holdings Inc.'s (NASDAQ:ESTA) Price
Establishment Labs Holdings Inc.'s ( NASDAQ:ESTA ) price-to-sales (or "P/S") ratio of 8.4x may look like a poor...Shareholder Returns
| ESTA | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -1.4% | 4.6% | 0.3% |
| 1Y | 97.7% | -21.2% | 19.9% |
Return vs Industry: ESTA exceeded the US Medical Equipment industry which returned -21.2% over the past year.
Return vs Market: ESTA exceeded the US Market which returned 19.9% over the past year.
Price Volatility
| ESTA volatility | |
|---|---|
| ESTA Average Weekly Movement | 7.3% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ESTA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ESTA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 1,004 | Fillipo Caldini | www.establishmentlabs.com |
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides breast tissue expanders.
Establishment Labs Holdings Inc. Fundamentals Summary
| ESTA fundamental statistics | |
|---|---|
| Market cap | US$2.57b |
| Earnings (TTM) | -US$43.74m |
| Revenue (TTM) | US$229.58m |
11.0x
P/S Ratio-57.7x
P/E RatioIs ESTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ESTA income statement (TTM) | |
|---|---|
| Revenue | US$229.58m |
| Cost of Revenue | US$68.74m |
| Gross Profit | US$160.84m |
| Other Expenses | US$204.57m |
| Earnings | -US$43.74m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.49 |
| Gross Margin | 70.06% |
| Net Profit Margin | -19.05% |
| Debt/Equity Ratio | 1,757.7% |
How did ESTA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/30 21:57 |
| End of Day Share Price | 2026/06/30 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Establishment Labs Holdings Inc. is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Neil Chatterji | B. Riley Securities, Inc. |
| Sam Eiber | BTIG |
| Michael Gorman | BTIG |